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TWO DISTINCT RENIN-ANGIOTENSIN systems (RAS) exist: the circulating RAS and the tissue-specific RAS. Although high salt intake (HSI) suppresses the circulating RAS, it aggravates kidney injury in chronic kidney disease (CKD). Activation of intrarenal RAS is involved in the progression of kidney fibrosis in CKD (17, 21) . However, little is known about the effect of HSI on intrarenal RAS activity in CKD. Prorenin is a precursor of renin and contains a prosegment that covers the enzymatic cleft and obstructs access of angiotensinogen to the active site of renin. On binding to the (pro)renin receptor (PRR), prorenin gains renin activity through nonproteolytic activation mediated by conformational changes, leading to unfolding of the prosegment from the enzymatic cleft, and becoming enzymatically active (22, 7) . The PRR-bound renin displays four to five times higher catalytic activity than free renin. The pathological role of the intrarenal receptor-mediated prorenin activation has been described in diabetic nephropathy rats and spontaneously hypertensive rats fed a high-salt diet (14, 15) . In the kidney, PRR was initially found in the arteries and glomerular mesangium (22) ; however, subsequent reports indicated it is localized mainly in the distal tubules (10, 23) and collecting ducts (2) . PRR is a multifunctional protein present in different molecular forms in the cells (2, 5) and is also known as ATP6ap2 (ATPase, H ϩ transporting, lysosomal accessory protein 2), which associates with vacuolar H ϩ -ATPase (V-ATPase), a mediator of urinary acidification and cellular pH homeostasis (25) . Advani et al. (2) reported colocalization of PRR with B1/2 subunits of V-ATPase in the collecting ducts and in the distal nephron, and PRR-mediated ERK1/2 phosphorylation in collecting duct/distal tubule lineage Madin-Darby canine kidney (MDCK) cells. It was also reported that PRR is a component of the Wnt receptor complex and functions as an adaptor between V-ATPase and Wnt receptor complexes (6) . These results suggest the cell surface localization of PRR (8) . Since HSI aggravates kidney injury in CKD despite suppressing circulating RAS activity, we hypothesized that HSI could activate intrarenal RAS through PRR-mediated prorenin activation. In this study, we investigated the levels and distribution of intrarenal prorenin, renin, and PRR, and receptor-mediated prorenin activation and ANG II generation in rats with chronic anti-thymocyte serum (ATS) nephritis on HSI. The effects of AT 1 receptor (AT1-R) blockade using olmesartan on intrarenal PRR-mediated prorenin activation and PRR distribution were also investigated in the nephritic rats on HSI. In addition, the effect of ANG II on the trafficking of PRR from the cytoplasm to the cell surface was investigated in vitro in MDCK cells.
METHODS
Experimental design. ATS was raised as described previously (27) . Chronic progressive ATS nephritis was induced by two consecutive injections of ATS, 1 wk apart, as reported previously (37) . To aggravate renal lesions, a unilateral nephrectomy was also performed. Male Wister rats (SLC, Hamamatsu, Japan), weighing 150 g, were ran-domly assigned into the following five groups; 1) SN group (n ϭ 8): rats were subjected to sham operation and provided tap water for drinking; 2) UA group (n ϭ 8): rats were subjected to uninephrectomy 7 days before the first ATS injection, received twice injections of 1 ml ATS through the tail vein on days 0 and 7, and provided tap water for drinking; 3) UAH group (n ϭ 8): rats were treated similarly to UA group but provided 0.5% sodium chloride solution for drinking; 4) UAHϩO group (n ϭ 8): rats treated similarly to the UAH group received olmesartan edoxomil (cs-866, Daiichi Sankyo, Tokyo, Japan) at 10 mg·kg Ϫ1 ·day Ϫ1 mixed in powdered food, started 7 days before the first ATS injection; and 5) UAHϩH group (n ϭ 8): rats treated similarly to the UAH group received hydralazine hydrochloride (Wako, Osaka, Japan) at 5 mg·kg Ϫ1 ·day Ϫ1 added to the drinking water, started 7 days before the first ATS injection. The doses of olmesartan medoxomil and hydralazine hydrochloride were controlled in each rat based on the consumed weight of powdered food and the volume of drinking water. Blood pressure was measured on days 14 and 21. Urine samples were collected for 24 h using metabolic cages. Rats were euthanized by decapitation on day 21, and blood samples and the kidneys were collected and prepared as described below. All animal procedures and experimental protocols were approved by the Ethics Review Committee for Animal Experimental of the Hamamatsu University School of Medicine.
Plasma renin activity and plasma and renal ANG II concentrations. Plasma renin activity (PRA) and plasma ANG II levels were measured by radioimmunoassay (RIA) kits (SRL, Tokyo, Japan). Intrarenal ANG II concentration was measured using a combination of solidphase extraction and RIA as described previously (26) .
Histopathological and immunohistochemical analyses. Kidney tissue sections and consecutive sections, 3 m thick, were stained with Masson's trichrome for histopathological analysis, and a standard biotin-streptavidin-peroxidase method was applied for immunohistochemical staining as described previously (27) . The primary antibodies were rabbit anti-renin antibody (generously provided by Dr. T. Inagami of Vanderbilt University, Nashville, TN), rabbit anti-gate region (GR) antibody that detects non-proteolytically activated prorenin, which exposes the GR in the prosegment mediated by conformational changes on binding to PRR (15) , goat anti-ATP6ap2/PRR antibody (Abcam, Tokyo, Japan), rabbit anti-ANG II antibody (Bachem, San Carlos, CA), rabbit anti-aquaporin-2 (AQP2) antibody (Calbiochem, San Diego, CA), and rabbit anti-calbindin-D-28k (EG-20) antibody (Sigma, St. Louis, MO). AQP2 was regarded as a marker for the collecting duct, and AQP2 labeling was also seen weakly on the basolateral membrane of the connecting tubule (24, 16) . Anti-calbindin-D-28k antibody was used to recognize the vitamin D-dependent calcium-binding protein, which was localized in the 50% of cells of the connecting tubule and initial collecting duct in the rat kidney (33) . As described in RESULTS, four distinct immunostaining patterns of PRR, including lumpy granular cytoplasmic, apical membranous, circumferential, and basolateral staining, were observed in some collecting duct and connecting tubular cells. The number of tubular cells with each immunostaining pattern was counted in 20 randomly selected cortical fields observed at ϫ400 magnification, and their proportions were calculated in each group.
Immunoblot analysis, trypsin pretreatment, and subcellular fractionation. Immunoblot analysis of cortical renin, prorenin, PRR, and AT1-R was conducted using a standard method as described previously (34) . To confirm the specificity of the anti-renin antibody that reacts with both renin and prorenin, we conducted trypsin pretreatment, which converts prorenin to renin. Renal cortical extracts were incubated with 0.25 or 0.5 g/l of trypsin (Sigma-Aldrich, Tokyo, Japan) for 60 min on ice. After stopping of the reaction with a trypsin inhibitor (Sigma-Aldrich), the samples were subjected to immunoblot analysis using an anti-renin antibody and anti-prosegment of prorenin antibody, which detects prorenin only. We also conducted subcellular fractionation using the ProteoExtract Subcellular Proteome Extraction Kit (Calbiochem, San Diego, CA) to determine the levels of cytoplasmic and membrane-bound PRR in the renal cortex. The primary antibodies included rabbit anti-renin antibody (a kind gift from Dr. T. Inagami), goat anti-PRR antibody that targets the intracellular domain of PRR of human origin (Santa Cruz Biotechnology, Santa Cruz, CA), rabbit anti-AT1-R antibody (Santa Cruz Biotechnology), rabbit antiprosegment of prorenin antibody (generously provided by Dr. F. Suzuki of Gifu University, Gifu, Japan), and mouse anti-␤-actin antibody (Sigma-Aldrich).
Quantitative real-time RT-PCR for PRR, renin, and transforming growth factor-␤1 mRNA. Quantitative real-time (QRT)-PCR was performed as described previously (27, 11) . The sequences of the primers used to detect specific genes were as follows: rat PRR: sense, 5=-ACACATCCCTG-GTGAGGAAG-3=, and antisense, 5=-AGGCCAAGCCAGTCATA-ATC-3=; rat renin: sense, 5=-TGGATCAGGGAAGGTCAAAG-3=, and antisense, 5=-TCGTGGGAGAGAATGTGGTC-3=; rat transforming growth factor (TGF)-␤1: sense, 5=-ACCGCAACAACGCAATCTAT-3=, and antisense, 5=-ACGCCAGGAATTGTTGCTAT-3=; and rat GAPDH: sense, 5=-CAGAACATCATCCCTGCATC-3=, and antisense, 5=-CTGCTTCACCACCTTCTTGA-3=. Data analysis was performed by using Light Cycler software (version 3.3.9; Roche). The mRNA level relative to that of GAPDH was calculated in each sample.
Cell surface PRR in MDCK cells. MDCK cells were cultured in DMEM/F12 (1:1) with 10% heat-inactivated FBS, streptomycin (100 g/ml), and penicillin (100 IU/ml) at 37°C in 95% humidified air-5% CO 2 in a CO2 incubator. The cell culture solutions and reagents were purchased from GIBCO (Grand Island, NY).
Semiconfluent MDCK cells were incubated in the serum-free medium for 24 h. Then, they were divided into the four groups, including the cells without treatment, those treated with 10 nM ANG II (Sigma-Aldrich), with 10 M olmesartan medoxomil, and with both 10 nM ANG II and 10 M olmesartan medoxomil, and were incubated for 4 h. Our preliminary experiment indicated that the levels of cell surface PRR peaked at 4-h incubation with 10 nM ANG II in MDCK cells (data not shown).
To measure the levels of cell surface PRR in MDCK cells, the cell surface proteins were biotinylated and isolated using the Pierce Cell Surface Protein Isolation Kit (Thermo Fisher Scientific, Rockford, IL) according to the manufacturer's instructions, and the levels of biotinylated cell surface PRR were detected by a standard immunoblot method with goat anti-ATP6ap2/PRR antibody (Abcam). The total cellular PRR protein levels were also detected similarly in the whole cell extracts. The protein concentrations were determined by a pyrogallol red-molybdate protein assay kit (Wako, Tokyo, Japan).
Statistical analysis. Data are expressed as means Ϯ SE. Statistical significance was tested using one-way ANOVA followed by Bonferroni's post hoc test. A P value Ͻ0.05 denoted the presence of a statistically significant difference.
RESULTS

Blood pressure and circulating RAS.
On day 14, the mean blood pressure (MBP) was not different between control rats on NSI (SN group), rats with chronic progressive ATS nephritis on NSI (UA group), rats with chronic progressive ATS nephritis on HSI (UAH group), and UAH rats treated with olmesartan (UAHϩO group) or hydralazine (UAHϩH group). On day 21, an increase in MBP was observed in the UAH group (Fig. 1A ). PRA and plasma ANG II levels on day 21 were decreased in the UA group, and the level of PRA was much lower in the UAH group. In rats with chronic progressive ATS nephritis on HSI, administration of olmesartan (UAHϩO) or hydralazine (UAHϩH) did not significantly change PRA or plasma ANG II levels compared with those in the UAH group (Fig. 1, B and C) .
Serum creatinine, proteinuria, TGF-␤1 mRNA in the renal cortex, and fibrotic renal lesions. The levels of serum creatinine, 24-h urinary protein excretion, TGF-␤1 mRNA expression, and fibrotic renal lesions were increased in the UA group and further enhanced in the UAH group (Fig. 2) . Treatment with olmesartan (UAHϩO group), but not hydralazine (UAHϩH group), attenuated these parameters.
Immunohistochemical analysis of total renin and non-proteolytically activated prorenin. To evaluate the intrarenal RAS, we first examined the immunohistochemical staining for total renin (Fig. 3A) , including renin and prorenin, and non-proteolytically activated prorenin (Fig. 3B ). Significant immunoreactivity was observed for total renin in the juxtaglomerular (JG) cells in the SN group; however, it was decreased slightly in the UA group and markedly suppressed in the UAH group. No significant immunoreactivity for total renin was noted in the tubules in the SN group. In contrast, immunoreactivity for total renin was noted in the collecting ducts and connecting tubules in the UA group and markedly augmented in the UAH group, where some proximal and distal tubules were also weakly positive (Fig. 3A) . Immunoreactivity for non-proteolytically activated prorenin was also observed in the JG cells in the SN group; however, it was decreased slightly in the UA group and markedly suppressed in the UAH group. No significant immunoreactivity for non-proteolytically activated prorenin was noted in the tubules in the SN group. In contrast, immunoreactivity for non-proteolytically activated prorenin was noted in some collecting ducts and connecting tubules in the UA group and significantly enhanced in the UAH group (Fig. 3B) . Under the HSI adopted in the present study, the levels of immunoreactivity for total renin and non-proteolytically activated prorenin in the JG cells in the nephritic rat on HSI treated with olmesartan (UAHϩO) and hydralazine (UAHϩH) did not significantly differ from those in the UAH group. In contrast, olmesartan treatment (UAHϩO) markedly diminished tubular total renin and non-proteolytically activated prorenin levels, while no significant changes were noted following hydralazine treatment (UAHϩH) (Fig. 3, A and B) .
Prorenin and renin proteins and renin mRNA in renal cortex. Western blot analysis using an anti-renin antibody resulted in the appearance of 60-and 55-kDa bands in rat renal cortical extracts. The molecular masses of these proteins were Values are means Ϯ SE. SN rats were subjected to sham operation and provided tap water for drinking; UA rats were subjected to uninephrectomy 7 days before the first anti-thymocyte serum (ATS) injection, received twice injections of 1 ml ATS through the tail vein on days 0 and 7, and provided tap water for drinking; UAH rats were treated similarly to UA group but provided 0.5% sodium chloride solution for drinking; UAHϩO rats were treated similarly to the UAH group but received olmesartan edoxomil at 10 mg·kg Ϫ1 ·day Ϫ1 mixed in powdered food, started 7 days before the first ATS injection; UAHϩH rats treated similarly to the UAH group received hydralazine hydrochloride at 5 mg·kg Ϫ1 ·day Ϫ1 added to the drinking water, started 7 days before the first ATS injection.*P Ͻ 0.05 vs. SN. #P Ͻ 0.05 vs. UAH. higher than the estimated molecular masses of prorenin and renin (45 and 38 kDa, respectively). To identify these bands, we conducted trypsin pretreatment, which converts prorenin to renin, followed by blotting with an anti-prosegment antibody, which detects prorenin only. Pretreatment with trypsin resulted in the disappearance of the 60-kDa band but increased the intensity of the 55-kDa band (Fig. 4A) , and the anti-prosegment antibody detected the 60-kDa band only (Fig. 4B) . These results indicated that the 60-and 55-kDa bands were prorenin and renin, respectively. In this regard, the presence of highmolecular mass glycosylated prorenin and renin of near 60 and 55 kDa, respectively, has been reported in the renal extract (1, 12, 29) .
Both cortical prorenin and renin proteins were enhanced markedly in the UAH group compared with the SN and UA groups. Treatment with olmesartan (UAHϩO) significantly reduced cortical prorenin levels, while hydralazine treatment (UAHϩH) had no significant effect (Fig. 4, C and D) . On the Fig. 4 . Immunoblot analysis for prorenin and renin proteins and renin mRNA expression in renal cortex. A and B: Western blot analysis using anti-renin antibody showed 60-and 55-kDa bands in rat renal cortical extracts. To identify these bands, we conducted trypsin pretreatment (A), which converts prorenin to renin, followed by blotting with anti-prosegment antibody (B), which detects prorenin only. Pretreatment with 0.25 as well as 0.5 g/l trypsin resulted in the disappearance of the 60-kDa band along with the increase in the 55-kDa band, and an anti-prosegment antibody detected the 60-kDa band only, indicating that the 60-and 55 kDa-bands were prorenin and renin, respectively. C and D: representative Western blot data of prorenin and renin in renal cortex on day 21 (C) and corresponding densitometric ratios of prorenin/␤-actin and renin/␤-actin in each group (D). E: cortical levels of renin mRNA measured by QRT-PCR. Values in D and E are means Ϯ SE. *P Ͻ 0.05 vs. SN. #P Ͻ 0.05 vs. UAH. Fig. 3 . Immunohistochemical demonstration of total renin, including prorenin and renin, and non-proteolytically activated prorenin in renal cortex. A: immunoreactivity for total renin. Significant immunoreactivity for total renin was observed in the juxtaglomerular (JG) cells in the SN group; however, it was decreased slightly in the UA group and was markedly suppressed in the UAH group. In contrast, immunoreactivity for total renin was noted in some collecting ducts and connecting tubules in the UA group and was markedly augmented in the UAH group, where some proximal and distal tubules were also weakly positive. B: immunoreactivity for non-proteolytically activated prorenin. The intensity and distribution of immunoreactivity for non-proteolytically activated prorenin in tubules were almost similar to those of total renin in each group. Olmesartan treatment (UAHϩO), but not hydralazine treatment (UAHϩH), markedly diminished tubular total renin and non-proteolytically activated prorenin. Original magnification ϫ400.
other hand, the level of renin mRNA was less in the UA group than in the SN group, and was further decreased in the UAH group (Fig. 4E) . Administration of olmesartan (UAHϩO) or hydralazine (UAHϩH) did not significantly change renal cortical renin mRNA levels in rats with chronic progressive ATS nephritis on HSI.
PRR protein and mRNA, and membrane-bound PRR in renal cortex. There were no significant differences in the renal cortical levels of PRR protein and mRNA in each group (Fig. 5, A-C) . However, subcellular fractionation analysis showed a marked increase in membrane-bound full-length PRR of 39 kDa in the UAH group, which was simultaneously accompanied by a decrease in its cytoplasmic fraction (Fig. 6, A-D) . Olmesartan (UAHϩO) decreased membrane-bound PRR and increased cytoplasmic PRR, while hydralazine (UAHϩH) had no significant effect.
Distribution and immunostaining pattern of PRR and expression of non-proteolytically activated prorenin and ANG II in consecutive kidney sections. Immunoreactivity for PRR was observed mainly in the collecting ducts, which were marked by positive staining for both AQP2 and calbindin-D-28k (24, 16, 33, 35) , and some connecting tubules, which were weakly positive for AQP2 (24, 16) and positive for calbindin-D-28k (33, 35) (Fig. 7A) . As a whole, the level of immunoreactivity for PRR in these tubules was not significantly different among the groups. However, changes in the immunostaining pattern of PRR were noted in the diseased kidneys. Lumpy granular cytoplasmic staining (open arrows in Fig. 7C ) in some collecting duct and connecting tubular cells was the predominant immunostaining pattern of PRR in the SN group (Fig. 7B) . In contrast, apical membranous PRR staining (arrows in Fig. 7C ) was found in some collecting duct and connecting tubular cells in the UA group and was augmented markedly in the UAH group (Fig. 7,  B and C) . A few collecting duct and connecting tubular cells showed a circumferential staining pattern (arrowheads in Fig.  7C ), and insignificant ones showed a basolateral staining pattern, and these populations were not significantly different among the groups. Olmesartan administration reduced apical membranous PRR immunostaining in the nephritic rat on HSI (UAHϩO); however, no significant changes were observed following hydralazine administration (UAHϩH) (Fig. 7B) .
Next, we mapped the distribution and investigated the interrelationship among non-proteolytically activated prorenin, PRR, and ANG II in consecutive kidney sections. The collecting duct and connecting tubular cells exhibiting lumpy granular cytoplasmic PRR immunostaining, which were observed mostly in the SN group, were negative or faintly positive for non-proteolytically activated prorenin and ANG II (Fig. 7C) . A few collecting duct and connecting tubular cells showing circumferential or basolateral PRR immunostaining were also negative for non-proteolytically activated prorenin and ANG II. In contrast, the collecting duct and connecting tubular cells with apical membranous PRR immunostaining, which were observed predominantly in the UAH group, were strongly positive for non-proteolytically activated prorenin and ANG II (Fig. 7C) .
AT1-R and ANG II levels in the renal cortex. No significant changes were noted in cortical AT1-R levels among the groups (Fig. 8, A and B) . The cortical ANG II levels were increased in the UA group and markedly augmented in the UAH group. Olmesartan, but not hydralazine, markedly decreased cortical ANG II levels (Fig. 8C) .
Effects of ANG II and olmesartan treatments on the cell surface PRR levels. The levels of full-length (39 kDa) PRR were increased significantly in the biotinylated cell surface protein extracts from MDCK cells treated with 10 nM ANG II and were suppressed by the addition of 10 M olmesartan, while no significant changes were noted in the levels of total cellular PRR by these treatments (Fig. 9) .
DISCUSSION
Despite the significant suppression of circulating RAS activity, which was associated with a reduction in total renin level in the JG cells, rats with chronic progressive ATS nephritis on HSI showed marked increases in tubular prorenin and renin proteins, non-proteolytically activated prorenin, cortical ANG II, and redistribution of PRR to the apical membrane mainly in the collecting ducts and connecting tubules. Enhanced tubular expression of renin through ANG IImediated AT1-R activation has been demonstrated in ANG II-infused hypertensive rats (30) . However, in rats with chronic progressive ATS nephritis on HSI, the cortical AT1-R level remained stable and that of renin mRNA was less than in non-nephritic rats on NSI. The discrepancy between renin mRNA expression and the levels of prorenin and renin proteins could be due to either protein uptake or ephemeral expression of the renin gene (13) . We cannot completely rule out the possible contribution of local tubular renin mRNA expression, because the level of renin mRNA measured by QRT-PCR in the renal cortical extract might have underestimated the local renin expression. In our study, marked increases in apical membrane PRR in the collecting duct and connecting tubules were noted in the nephritic kidneys on HSI, even if total cortical PRR levels were similar in non-nephritic rats on NSI and in the nephritic kidneys on HSI. Furthermore, subcellular fractionation studies also showed elevated PRR abundance in the membrane, with concomitant decreases in the cytoplasmic fractions; in other words, enhanced apical membrane trafficking of PRR was observed in the nephritic kidneys on HSI. In consecutive kidney sections, the collecting duct and connecting tubular cells with apical membranous PRR immunostaining, which were observed predominantly in the UAH group, were strongly positive for non-proteolytically activated prorenin and ANG II. Therefore, it is likely that the increased tubular apical membrane PRR would lead to further binding of prorenin and renin, with the nonproteolytic activation of additional prorenin, resulting in increased ANG II levels.
It was recently demonstrated that PRR is an accessory protein which is associated with V-ATPase in the collecting ducts (2) . ANG II induces redistribution of V-ATPase from the cytoplasmic vesicles to the apical plasma membrane in type A intercalated cells in the collecting ducts (28) . ANG II-mediated trafficking of V-ATPase from the cytoplasm to the plasma membrane, resulting in the augmentation of cell surface expression of V-ATPase, was also reported in a SV40-transformed cell line derived from rat proximal tubules (IRPTC) (4) . In the present study, we also demonstrated that ANG II significantly increased the levels of cell surface PRR without changing total cellular PRR levels and olmesartan significantly suppressed the ANG II-induced increase in cell surface PRR in MDCK cells, a collecting duct cell line. These data further Olmesartan treatment in the nephritic rats on HSI (UAHϩO) produced significant decreases in cortical prorenin and ANG II levels, without significant decreases in renin levels. A potential reason for the observed phenomenon would be the three times more binding affinity of PRR for prorenin than renin (3). The decrease in apical membrane PRR by olmesartan could have a greater effect on the PRR-bound levels of prorenin than renin in the collecting ducts and connecting tubules. Subsequent decreases in nonproteolytical activation of prorenin and ANG I generation would lead to reduction of cortical ANG II levels and the attenuation of renal lesions in the UAHϩO group. Mazzolai et al. (20) reported that losartan decreased tissue ANG II in mice despite increased plasma levels and suggested that losartan may have prevented excessive ANG II from being protected against angiotensinases in the tissues. This mechanism may also be involved in the decrease in cortical ANG II in the UAHϩO group. From these points of view, the enhanced cortical ANG II may be not only a consequence but also a cause of upregulation of the apical membrane PRR in chronic progressive ATS nephritis rat kidneys on HSI. Therefore, a possibility remains that the above-mentioned changes noted in the UAHϩO group may be the secondary features of olmesartan, which are attributed to the amelioration of fibrotic renal lesions induced by ANG II.
Under the HSI adopted in the present study, the levels of immunoreactivity for total renin and non-proteolytically activated prorenin in the JG cells of UAHϩO rats did not significantly differ from those in the untreated UAH group. We consider that because the salt intake of 0.5% sodium chloride solution for drinking was so strong that renin expression in the JG cells was not stimulated by 10 mg·kg Ϫ1 ·day Ϫ1 olmesartan mixed in the food of UAHϩO rats. These data were compatible with the lack of significant increases in plasma renin activity, plasma ANG II, and renal cortical renin mRNA expression in the UHAϩO group compared with the UAH group. When one considers that olmesartan suppressed the cell surface trafficking of PRR in the collecting ducts and connecting tubules, it seems likely that olmesartan did not stimulate nonproteolytic activation of prorenin mediated by its binding to PRR in the JG cells.
The origin of the excess prorenin and renin in tubules remains to be clarified in this study. Although renin originates from the JG cells, prorenin has been shown to be produced by not only the JG cells but also the principal cells in collecting duct (31) , glomerular podocytes (18), ovary, placenta, testis, adrenals, and renina (9) . Because the levels of plasma renin activity, immmunoreactivity for total renin in the JG cells, and renal cortical expression of renin mRNA were suppressed in the UAH group, it is plausible to speculate that the expression and release of prorenin and renin from the JG cells, and those of prorenin from the principal cells in collecting ducts and glomerular podocytes, were insignificant in this condition. Therefore, the most prorenin, which was increased and nonproteolytically activated in the collecting ducts, may be of nonrenal origin in the UAH group. The plasma prorenin level is 10 times more than renin; the increase in plasma prorenin has been shown to be related to the microvascular complications including nephropathy, retinopathy, and neuropathy in diabetic patients (36, 19) . Although most proteins that filtered through the glomerular capillary are reabsorbed in the proximal tubules under normal conditions, significant amounts of plasma proteins are released into urine in the nephritic condition with heavy proteinuria. Significant amounts of prorenin and renin have been detected in the urine of mice treated with a high-salt diet (32) . It is therefore possible that some prorenin and renin in plasma could reach the collecting ducts in the UAH group. Further studies that investigate the urinary levels of prorenin, renin, and ANG II are needed to confirm the origin of increased tubular prorein and renin proteins in the nephritic rats on HSI.
In conclusion, the data in the present study suggested the involvement of an ANG II-dependent increase in apical membrane PRR in the augmentation of intrarenal binding of prorenin and renin, followed by nonproteolytic activation of prorenin, enhancement of renin catalytic activity, ANG II generation, and progression of kidney fibrosis in the nephritic rat kidneys on HSI despite the significant suppression of circulating RAS activity. The origin of the increased tubular prorenin and renin remains to be clarified, and further studies measuring urinary prorenin and renin are needed.
